Gennex Laboratories Ltd
Gennex Laboratories Ltd (GENNEX) last reported results for the quarter ended Jun 2026, with sales of ₹39.84 crore and net profit of ₹4.67 crore. The stock last traded at ₹9.95, a market capitalisation of ₹242 crore, on a P/E of 12.9. Over the past 52 weeks the stock has ranged between ₹7.05 and ₹17.2. Figures are as of 6 Oct 2026 and are not real time.
Gennex Laboratories Ltd share price and key metrics
- Current price
- ₹9.95
- Market cap
- ₹242 cr
- Stock P/E
- 12.9
- Book value
- ₹9.16
- ROE
- 10.5%
- ROCE
- 11.8%
- Dividend yield
- 0.00%
- 52w high / low
- 17.2/7.05
Metrics as of 6 Oct 2026. Not real time.
Track Gennex Laboratories Ltd
Cruxal reads every Gennex Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Gennex Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 38%
- TTM
- 24%
- 10 Years
- %
- 5 Years
- 38%
- 3 Years
- 64%
- TTM
- 14%
- 10 Years
- 4%
- 5 Years
- 8%
- 3 Years
- -4%
- 1 Year
- -22%
- 10 Years
- 9%
- 5 Years
- 10%
- 3 Years
- 10%
- Last Year
- 11%
Gennex Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹39.84 cr, up 16.6% from ₹34.18 cr a year earlier. Net profit was ₹4.67 cr, down 6.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 33.38 | 40.01 | 40.33 | 34.18 | 39.3 | 42.96 | 60.96 | 39.84 |
| Expenses | 25.92 | 32.86 | 38.31 | 29.11 | 31.74 | 34.39 | 55.07 | 35.46 |
| Operating profit | 7.46 | 7.15 | 2.02 | 5.07 | 7.56 | 8.57 | 5.89 | 4.38 |
| OPM % | 22.35% | 17.87% | 5.01% | 14.83% | 19.24% | 19.95% | 9.66% | 10.99% |
| Other income | 0 | 0 | 3.68 | 2.28 | 0 | -0.3 | 1.02 | 2.01 |
| Interest | 0.22 | 0.84 | 1.2 | 0.98 | 1.03 | 1.11 | 1.08 | 0.57 |
| Depreciation | 1.11 | 0.5 | 0.54 | 0.5 | 0.47 | 0.52 | 1.16 | 0.9 |
| Profit before tax | 6.13 | 5.81 | 3.96 | 5.87 | 6.06 | 6.64 | 4.67 | 4.92 |
| Tax % | 12.23% | 12.91% | 22.22% | 14.48% | 9.08% | 9.79% | 4.50% | 5.08% |
| Net profit | 5.38 | 5.06 | 3.07 | 5.01 | 5.51 | 6 | 4.46 | 4.67 |
| EPS (₹) | 0.21 | 0.20 | 0.10 | 0.20 | 0.21 | 0.22 | 0.15 | 0.18 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gennex Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 173 | 183 |
| Operating profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 22 | 26 |
| OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 20% | 12% | 13% | 14% |
| Net profit | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 21 | 21 |
| EPS (₹) | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.58 | 0.80 | 0.86 | 0.76 |
TTM is the trailing twelve months to the most recent quarter.
Gennex Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 | 24 |
| Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 148 | 164 | 198 |
| Borrowings | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 6 | 10 | 36 |
| Other liabilities | 14 | 16 | 13 | 16 | 12 | 14 | 51 | 54 | 59 | 90 |
| Total liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 349 |
| Fixed assets | 16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | 61 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 13 |
| Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Other assets | 26 | 28 | 29 | 35 | 38 | 48 | 59 | 172 | 191 | 275 |
| Total assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 349 |
As reported by the company. Total assets equal total liabilities by construction.
Gennex Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0 | 3 | 2 | -2 | -1 | 12 | 24 | -47 | -10 | -64 |
| Cash from investing | -1 | -1 | -1 | -0 | -0 | -2 | -38 | 19 | 3 | -5 |
| Cash from financing | 1 | -2 | 1 | -0 | 2 | -2 | 21 | 74 | 2 | 65 |
| Net cash flow | -0 | 0 | 2 | -2 | 0 | 8 | 6 | 46 | -5 | -3 |
| Free cash flow | -1 | 2 | 1 | -2 | -2 | 10 | -16 | -31 | -15 | -76 |
| CFO / operating profit | 13% | 190% | 55% | -52% | 1% | 242% | 505% | -274% | -39% | -274% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Gennex Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 6% | 11% | 8% | 14% | 12% | 11% | 14% | 13% | 12% |
| Debtor days | 90 | 87 | 68 | 41 | 55 | 67 | 52 | 75 | 37 | 92 |
| Inventory days | 43 | 31 | 57 | 78 | 50 | 72 | 139 | 184 | 133 | 152 |
| Days payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 | 111 | 49 | 57 |
| Cash conversion cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 | 148 | 122 | 187 |
| Working capital days | 74 | 75 | 56 | 87 | 108 | 87 | 23 | 255 | 214 | 295 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Gennex Laboratories Ltd shareholding pattern
Promoters held 23.63% at Jun 2026, up from 19.82% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 18.41% | 18.41% | 18.41% | 19.82% | 23.62% | 23.62% | 23.63% | 23.63% |
| Public | 81.59% | 81.58% | 81.58% | 80.17% | 76.38% | 76.39% | 76.36% | 76.38% |
| No. of shareholders | 90,236 | 92,506 | 92,326 | 91,183 | 90,320 | 86,306 | 84,133 | 82,886 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Gennex Laboratories Ltd corporate filings
- Gennex Laboratories Limited's Voting Results Confirm Re-election of Key Directors and Approval of FinancialsAGM/EGMhigh impact
Cruxal's analysis: Gennex Laboratories Limited reported that all resolutions at its 41st AGM held on…
Read the full analysis - Gennex Laboratories Limited appoints Mr. Dipankar Dasgupta as Independent Director effective October 01, 2026, replacing retiring director Mr. Amudala Sreeramulu Nageswar Rao, with no immediate change in shareholding or derivative positions.Company Updatelow impact
Cruxal's analysis: Gennex Laboratories Limited has announced the appointment of Mr. Dipankar Dasgupta as an…
Read the full analysis - Gennex Laboratories' 41st AGM indicates ongoing corporate governance and strategic discussions, but no immediate financial or operational disclosures impacting valuation.AGM/EGMlow impact
Cruxal's analysis: The company held its 41st AGM on September 30, 2026, via video conferencing, with 47…
Read the full analysis - Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window ....Insider Trading / SASTlow impact
- Gennex Laboratories Limited Announces 41st Annual General Meeting for September 30, 2026Company Updatelow impact
Cruxal's analysis: Gennex Laboratories Limited has issued a formal notice for its 41st Annual General…
Read the full analysis - Gennex Laboratories subsidiary Deccan Remedies receives manufacturing and test license approvalsCompany Updatelow impact
Cruxal's analysis: Gennex Laboratories Ltd announced that its subsidiary, Deccan Remedies Limited, has…
Read the full analysis - Gennex Laboratories Ltd submits 41st Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Gennex Laboratories has filed its 41st Annual Report for the financial year ended March…
Read the full analysis - Gennex Laboratories Limited schedules Board Meeting for September 04, 2026, to finalize 41st AGM detailsBoard Meetinglow impact
Cruxal's analysis: Gennex Laboratories Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis - Gennex Laboratories Limited Reports Q1 FY2027 Financial Results with Consolidated Net Profit of 4.66 croreCompany Updatelow impact
Cruxal's analysis: Gennex Laboratories Limited has released its unaudited financial results for the quarter…
Read the full analysis - Gennex Laboratories Limited Reports Q1 FY2027 Financial Results with Standalone Net Profit of 3.96 CroreBoard Meetingmedium impact
Cruxal's analysis: Gennex Laboratories Limited has released its unaudited financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.